Two members of the retinoblastoma pathway, TOP2A and CDK1, were further shown as potential diagnostic biomarkers to distinguish leiomyomas from leiomyosarcomas and as prognostic tools in leiomyosarcoma patients. Here, TOP2A is linked to leiomyosarcoma.